PE-22-28
Also known as: PE-22-28, Spadin analog
A spadin-derived peptide studied as a fast-acting antidepressant candidate that works by blocking the TREK-1 potassium channel, with reported neurogenic and neuroprotective effects.
Last updated
Mechanism of Action
PE-22-28 is a shortened analog of spadin that selectively blocks the TREK-1 (two-pore-domain) potassium channel, a target implicated in depression. TREK-1 inhibition increases neuronal excitability and is reported to promote rapid antidepressant effects and hippocampal neurogenesis in preclinical models. It has also been investigated for neuroprotection in stroke models, reflecting TREK-1's broader role in the nervous system.
- Half-life
- Not well characterized in humans
- Administration Routes
- subcutaneous, intranasal
- Research Status
- Preclinical
Reported Benefits
- Reported fast-acting antidepressant effects in animal models
- Promotes hippocampal neurogenesis in preclinical research
- Selective TREK-1 channel blockade
- Investigated for neuroprotection in stroke
- Novel mechanism distinct from SSRIs
Potential Side Effects
- Very limited human safety data
- Theoretical effects on cardiac TREK channels
- Injection-site or intranasal irritation
- Purity and dosing uncertainty as a research chemical
Common Dosing
Preclinical research uses microgram-range dosing in animal models; human protocols are not established. Educational reference only, not advice.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Cardiac arrhythmia (theoretical, TREK channel involvement)
- Pregnancy or breastfeeding
- Not approved for human use; minimal safety data
Semax
A synthetic peptide derived from ACTH(4-10) developed in Russia and used there for cognitive enhancement, stroke recovery, and neuroprotection. Often used intranasally.
Selank
A synthetic analog of the immunomodulatory peptide tuftsin developed in Russia for anxiety reduction and cognitive support without the sedation or dependence of benzodiazepines.
- View
Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity
2017
- View
First evidence of protective effects on stroke recovery and post-stroke depression induced by sortilin-derived peptides
2019
- View
Sortilin-derived peptides promote pancreatic beta-cell survival through CREB signaling pathway.
2021
- View
Fighting against depression with TREK-1 blockers: Past and future. A focus on spadin.
2019